RxDoctor Payments Data

Brenda James

Nurse Practitioner · Norman, OKNPI 1700808144

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 291 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,143 and has fallen 83.9% since, to $345 in 2025. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,547in general payments, 2019–2025

Across 291 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$735
  • AbbVie$655
  • Teva Pharmaceuticals USA, Inc.$579
  • Otsuka America Pharmaceutical, Inc.$551
  • Johnson & Johnson$336
  • Corium, LLC$328
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,49899%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,547 in reported general payments places this provider in the 90th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl15$24,897
RexultiBrexpiprazole14$21,656
Venlafaxine Hcl ErVenlafaxine Hcl14$936
Bupropion XlBupropion Hcl17$482
Buspirone Hcl24$447
Duloxetine Hcl22$439
Quetiapine Fumarate32$430
Aripiprazole13$345
Trazodone Hcl23$311
Bupropion Hcl SrBupropion Hcl18$249
Divalproex Sodium13$232
Clonazepam20$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$655$24,89715 claims
Otsuka America Pharmaceutical, Inc.Rexulti$551$21,65614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →